AstraZeneca's Fasenra Fails in Trial of Severe Lung Disease
- Drugmaker is still conducting another test of the drug
- AstraZenaca has been trying to expand treatment beyond asthma
This article is for subscribers only.
AstraZeneca Plc’s Fasenra failed to meet its goal in a late-stage trial of patients with chronic obstructive pulmonary disease, a blow for the company as it tries to expand the market for the drug.
Fasenra, already approved for treatment of severe asthma, was tested in about 2,000 patients to see whether it would reduce exacerbations of COPD, according to Cambridge, England-based Astra. The company is still conducting another trial in about the same number of patients, according to a statement Friday.